Cardiovascular disease in diabetes: Where does glucose fit in?

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 8, 2011, Pages 2367-2376

  Reusch, Jane E B ^a,b   Low Wang, Cecilia C ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLICLAZIDE; GLINIDE; GLITAZONE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN SECRETAGOGUE; SULFONYLUREA; UNCLASSIFIED DRUG;

ATHEROGENESIS; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CELL ACTIVATION; COHORT ANALYSIS; CORRELATION ANALYSIS; DIABETES CONTROL; DIABETES MELLITUS; DISEASE COURSE; ENDOTHELIUM CELL; EPIDEMIOLOGY; FIBROBLAST; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INFLAMMATORY CELL; MICROANGIOPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGISTER; REVIEW; SWEDEN; THROMBOCYTE ACTIVATION; VASCULAR SMOOTH MUSCLE;

BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETIC ANGIOPATHIES; HUMANS; HYPERGLYCEMIA;

EID: 79961224054     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2010-3011     Document Type: Review

References (69)

1. Reusch JE, Draznin BB 2007 Atherosclerosis in diabetes and insulin resistance. Diabetes Obes Metab 9:455-463 (Pubitemid 47022828)
2. Wang CC, Goalstone ML, Draznin B 2004 Molecular mechanisms of insulin resistance that impact cardiovascular biology. Diabetes 53:2735-2740 (Pubitemid 39425897)
3. Sitia S, Tomasoni L, Atzeni F, Ambrosio G, Cordiano C, Catapano A, Tramontana S, Perticone F, Naccarato P, Camici P, Picano E, Cortigiani L, Bevilacqua M, Milazzo L, Cusi D, Barlassina C, Sarzi-Puttini P, Turiel M 2010 From endothelial dysfunction to atherosclerosis. Autoimmun Rev 9:830-834
4. Colwell JA, Winocour PD, Lopes-Virella M, Halushka PV 1983 New concepts about the pathogenesis of atherosclerosis in diabetes mellitus. Am J Med 75:67-80 (Pubitemid 14218795)
5. Ceriello A, Esposito K, Piconi L, Ihnat MA, Thorpe JE, Testa R, Boemi M, Giugliano D 2008 Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes 57:1349-1354
6. Otsuka A, Azuma K, Iesaki T, Sato F, Hirose T, Shimizu T, Tanaka Y, Daida H, Kawamori R, Watada H 2005 Temporary hyperglycaemia provokes monocyte adhesion to endothelial cells in rat thoracic aorta. Diabetologia 48:2667-2674 (Pubitemid 41738236)
7. Pandolfi A, Giaccari A, Cilli C, Alberta MM, Morviducci L, DeFilippis EA, Buongiorno A, Pellegrini G, Capani F, Consoli A 2001 Acute hyperglycemia and acute hyperinsulinemia decrease plasma fibrinolytic activity and increase plasminogen activator inhibitor type 1 in the rat. Acta Diabetol 38:71-76 (Pubitemid 33035314)
8. Zuurbier CJ, Demirci C, Koeman A, Vink H, Ince C 2005 Short-term hyperglycemia increases endothelial glycocalyx permeability and acutely decreases lineal density of capillaries with flowing red blood cells. J Appl Physiol 99:1471-1476 (Pubitemid 43014356)
9. Velusamy T, Jain SK 2011 Effects of high glucose and ketosis (acetoacetate, β-hydroxybutyrate) on PAI-1 secretion in human umbilical vascular endothelial cells. Clin Appl Thromb Hemost 17:288-292
10. Zhong W, Zou G, Gu J, Zhang J 2010 L-Arginine attenuates high glucose-accelerated senescence in human umbilical vein endothelial cells. Diabetes Res Clin Pract 89:38-45
11. Piga R, Naito Y, Kokura S, Handa O, Yoshikawa T 2009 Inhibitory effect of serotonin derivatives on high glucose-induced adhesion and migration of monocytes on human aortic endothelial cells. Brit J Nutr 102:264-272
12. Tang R, Li Q, Lv L, Dai H, Zheng M, Ma K, Liu B 2010 Angiotensin II mediates the high-glucose-induced endothelial-to-mesenchymal transition in human aortic endothelial cells. Cardiovasc Diabetol 9:31
13. Colwell JA, Nesto RW 2003 The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care 26:2181-2188
14. Inoguchi T, Yu HY, Imamura M, Kakimoto M, Kuroki T, Maruyama T, Nawata H 2001 Altered gap junction activity in cardiovascular tissues of diabetes. Med Electron Microsc 34:86-91
15. Li AF, Roy S 2009 High glucose-induced downregulation of connexin 43 expression promotes apoptosis in microvascular endothelial cells. Invest Ophthalmol Vis Sci 50:1400-1407
16. Makino A, Platoshyn O, Suarez J, Yuan JX, Dillmann WH 2008 Downregulation of connexin40 is associated with coronary endothelial cell dysfunction in streptozotocin-induced diabetic mice. Am J Physiol Cell Physiol 295:C221-C230 (Pubitemid 352755806)
17. Dong L, Zheng YM, Van Riper D, Rathore R, Liu QH, Singer HA, Wang YX 2008 Functional and molecular evidence for impairment of calcium-activated potassium channels in type-1 diabetic cerebral artery smooth muscle cells. J Cereb Blood Flow Metab 28:377-386 (Pubitemid 351161293)
18. Meng L, Park J, Cai Q, Lanting L, Reddy MA, Natarajan R 2010 Diabetic conditions promote binding of monocytes to vascular smooth muscle cells and their subsequent differentiation. Am J Physiol Heart Circ Physiol 298:H736-H745
19. El-Osta A, Brasacchio D, Yao D, Pocai A, Jones PL, Roeder RG, Cooper ME, Brownlee M 2008 Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med 205:2409-2417
20. Villeneuve LM, Reddy MA, Lanting LL, Wang M, Meng L, Natarajan R 2008 Epigenetic histone H3 lysine 9 methylation in metabolic memory and inflammatory phenotype of vascular smooth muscle cells in diabetes. Proc Natl Acad Sci USA 105:9047-9052
21. Tonna S, El-Osta A, Cooper ME, Tikellis C 2010 Metabolic memory and diabetic nephropathy: potential role for epigenetic mechanisms. Nat Rev Nephrol 6:332-341
22. Eckel RH, Wassef M, Chait A, Sobel B, Barrett E, King G, Lopes-Virella M, Reusch J, Ruderman N, Steiner G, Vlassara H 2002 Prevention Conference VI: Diabetes and Cardiovascular Disease Writing Group II. Pathogenesis of atherosclerosis in diabetes. Circulation 105:e138-143
23. Lima VV, Giachini FR, Hardy DM, Webb RC, Tostes RC 2011 O-GlcN acylation: a novel pathway contributing to the effects of endothelin in the vasculature. Am J Physiol Regul Integr Comp Physiol 300:R236-R250
24. Brownlee M 2005 The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54:1615-1625 (Pubitemid 40770750)
25. Du X, Matsumura T, Edelstein D, Rossetti L, Zsengellér Z, Szabó C, Brownlee M 2003 Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest 112:1049-1057 (Pubitemid 38056320)
26. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M 1998 Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229-234 (Pubitemid 28350165)
27. Schraer CD, Adler AI, Mayer AM, Halderson KR, Trimble BA 1997 Diabetes complications and mortality among Alaska natives: 8 years of observation. Diabetes Care 20:314-321 (Pubitemid 27098217)
28. Sheridan S, Pignone M, Mulrow C 2003 Framingham-based tools to calculate the global risk of coronary heart disease: a systematic review of tools for clinicians. J Gen Intern Med 18:1039-1052 (Pubitemid 38091400)
29. Tzoulaki I, Liberopoulos G, Ioannidis JP 2009 Assessment of claims of improved prediction beyond the Framingham risk score. JAMA 302:2345-2352
30. Grundy SM, Cleeman JI, Merz CN, Brewer Jr HB, Clark LT, Hunninghake DB, Pasternak RC, Smith Jr SC, Stone NJ 2004 Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110:227-239 (Pubitemid 38924592)
31. Feeman Jr WE 2010 Diabetes mellitus is not a coronary heart disease equivalent. Am J Cardiol 106:754-755
32. Saely CH, Aczel S, Koch L, Schmid F, Marte T, Huber K, Drexel H 2010 Diabetes as a coronary artery disease risk equivalent: before a change of paradigm? Eur J Cardiovasc Prev Rehabil 17:94-99
33. Sprafka JM, Burke GL, Folsom AR, McGovern PG, Hahn LP 1991 Trends in prevalence of diabetes mellitus in patients with myocardial infarction and effect of diabetes on survival. The Minnesota Heart Survey. Diabetes Care 14:537-543
34. Ledru F, Ducimetière P, Battaglia S, Courbon D, Beverelli F, Guize L, Guermonprez JL, Diébold B 2001 New diagnostic criteria for diabetes and coronary artery disease: insights from an angiographic study. J Am Coll Cardiol 37:1543-1550
35. McGill Jr HC, McMahan CA, Malcom GT, Oalmann MC, Strong JP 1995 Relation of glycohemoglobin and adiposity to atherosclerosis in youth. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Arterioscler Thromb Vasc Biol 15:431-440
36. Jaffe AS, Spadaro JJ, Schechtman K, Roberts R, Geltman EM, Sobel BE 1984 Increased congestive heart failure after myocardial infarction of modest extent in patients with diabetes mellitus. Am Heart J 108:31-37 (Pubitemid 14087965)
37. Balkau B, Shipley M, Jarrett RJ, Pyörälä K, Pyörälä M, Forhan A, Eschwège E 1998 High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men: 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care 21:360-367 (Pubitemid 28101069)
38. Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, Stampfer M, Stehouwer CD, Lewington S, Pennells L, Thompson A, Sattar N, White IR, Ray KK, Danesh J 2010 Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 375:2215-2222
39. Kuusisto J, Laakso M 1999 Prandial glucose regulation and cardiovascular disease in type 2 diabetes. Eur J Clin Invest 29(Suppl 2):7-11 (Pubitemid 29267935)
40. Wilson PW, Cupples LA, Kannel WB 1991 Is hyperglycemia associated with cardiovascular disease? The Framingham Study. Am Heart J 121:586-590
41. Wei M, Gaskill SP, Haffner SM, Stern MP 1998 Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study. Diabetes Care 21:1167-1172 (Pubitemid 28368527)
42. Standl E, Balletshofer B, Dahl B, Weichenhain B, Stiegler H, Hörmann A, Holle R 1996 Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: the Munich General Practitioner Project. Diabetologia 39:1540-1545 (Pubitemid 26397365)
43. 1998 Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:837-853
44. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, Holman RR 1998 Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 316:823-828 (Pubitemid 28112428)
45. Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, Pankow J, Coresh J, Brancati FL 2010 Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 362:800-811
46. Selvin E, Wattanakit K, Steffes MW, Coresh J, Sharrett AR 2006 HbA1c and peripheral arterial disease in diabetes: the Atherosclerosis Risk in Communities study. Diabetes Care 29:877-882 (Pubitemid 44115310)
47. Eeg-Olofsson K, Cederholm J, Nilsson PM, Zethelius B, Svensson AM, Gudbjörnsdóttir S, Eliasson B 2010 New aspects of HbA1c as a risk factor for cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR). J Intern Med 268:471-482
48. Eeg-Olofsson K, Cederholm J, Nilsson PM, Zethelius B, Svensson AM, Gudbjörnsdóttir S, Eliasson B 2010 Glycemic control and cardiovascular disease in 7,454 patients with type 1 diabetes: an observational study from the Swedish National Diabetes Register (NDR). Diabetes Care 33:1640-1646
49. Rodriguez BL, Lau N, Burchfiel CM, Abbott RD, Sharp DS, Yano K, Curb JD 1999 Glucose intolerance and 23-year risk of coronary heart disease and total mortality: the Honolulu Heart Program. Diabetes Care 22:1262-1265 (Pubitemid 29350234)
50. Balkau B, Hu G, Qiao Q, Tuomilehto J, Borch-Johnsen K, Pyörälä K 2004 Prediction of the risk of cardiovascular mortality using a score that includes glucose as a risk factor. The DECODE Study. Diabetologia 47:2118-2128 (Pubitemid 40174684)
51. Esposito K, Giugliano D, Nappo F, Marfella R 2004 Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 110:214-219 (Pubitemid 38924590)
52. Bibra H, Siegmund T, Ceriello A, Volozhyna M, Schumm-Draeger PM 2009 Optimized postprandial glucose control is associated with improved cardiac/vascular function - comparison of three insulin regimens in well-controlled type 2 diabetes. Horm Metab Res 41:109-115
53. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B 2005 Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353:2643-2653 (Pubitemid 41817713)
54. 1993 The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 329:977-986
55. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA 2008 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577-1589
56. Gerstein HC, Miller ME, Byington RP, Goff Jr DC, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm Jr RH, Probstfield JL, Simons-Morton DG, Friedewald WT 2008 Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545-2559 (Pubitemid 351831356)
57. Gerstein HC, Miller ME, Genuth S, Ismail-Beigi F, Buse JB, Goff Jr DC, Probstfield JL, Cushman WC, Ginsberg HN, Bigger JT, Grimm Jr RH, Byington RP, Rosenberg YD, Friedewald WT 2011 Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 364:818-828
58. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F 2008 Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560-2572 (Pubitemid 351831357)
59. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD 2009 Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360:129-139
60. Bonds DE, Miller ME, Bergenstal RM, Buse JB, Byington RP, Cutler JA, Dudl RJ, Ismail-Beigi F, Kimel AR, Hoogwerf B, Horowitz KR, Savage PJ, Seaquist ER, Simmons DL, Sivitz WI, Speril-Hillen JM, Sweeney ME 2010 The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 340:b4909
61. Calles-Escandón J, Lovato LC, Simons-Morton DG, Kendall DM, Pop-Busui R, Cohen RM, Bonds DE, Fonseca VA, Ismail-Beigi F, Banerji MA, Failor A, Hamilton B 2010 Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care 33:721-727
62. Miller ME, Bonds DE, Gerstein HC, Seaquist ER, Bergenstal RM, Calles-Escandon J, Childress RD, Craven TE, Cuddihy RM, Dailey G, Feinglos MN, Ismail-Beigi F, Largay JF, O'Connor PJ, Paul T, Savage PJ, Schubart UK, Sood A, Genuth S 2010 The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ 340:b5444
63. Riddle MC, Ambrosius WT, Brillon DJ, Buse JB, Byington RP, Cohen RM, Goff Jr DC, Malozowski S, Margolis KL, Probstfield JL, Schnall A, Seaquist ER 2010 Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care 33:983-990
64. Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, Billot L, Woodward M, Ninomiya T, Neal B, MacMahon S, Grobbee DE, Kengne AP, Marre M, Heller S 2010 Severe hypoglycemia and risks of vascular events and death. N Engl J Med 363:1410-1418
65. Reaven PD, Moritz TE, Schwenke DC, Anderson RJ, Criqui M, Detrano R, Emanuele N, Kayshap M, Marks J, Mudaliar S, Harsha Rao R, Shah JH, Goldman S, Reda DJ, McCarren M, Abraira C, Duckworth W 2009 Intensive glucose-lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis. Diabetes 58:2642-2648
66. Brown A, Reynolds LR, Bruemmer D 2010 Intensive glycemic control and cardiovascular disease: an update. Nat Rev Cardiol 7:369-375
67. Skyler JS 2010 Glycemia and cardiovascular diseases in type 2 diabetes. J Intern Med 268:468-470
68. Hirsch IB, Brownlee M 2010 Beyond hemoglobin A1c-need for additional markers of risk for diabetic microvascular complications. JAMA 303:2291-2292
69. Abraira C, Duckworth WC, Moritz T; VADT Group 2009 Glycaemic separation and risk factor control in the Veterans Affairs Diabetes Trial: an interim report. Diabetes Obes Metab 11:150-1561